In vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against gram-negative bacilli.
We investigated in vitro activities of piperacillin or cefoperazone alone and in combination with beta-lactamase inhibitors against Gram-negative bacilli. Piperacillin/tazobactam 8:1 lowered resistance for Escherichia coli, Serratia marcescens, Enterobactaer cloacae, Klebsiella pneumoniae and imipenem-susceptible Acinetobacter baumannii. When piperacillin was combined with sulbactam 2:1 or 4:1, resistance against E. coli, S. marcescens, E. cloacae, extended spectrum beta-lactamase (ESBL)-K. pneumoniae and A. baumannii were reduced. MIC90 of cefoperazone against S. marcescens, E. cloacae, ESBL-K. pneumoniae and A. baumannii were >128 mg/L. Addition of sulbactam 1:1 or 2:1 enhanced antimicrobial activities. Addition of sulbactam to piperacillin or cefoperazone enhanced antimicrobial activities of GNB.
Kuo
Han-Yueh
HY
Division of Infectious Diseases, Department of Medicine, Hsin-Chu General Hospital, Department of Health, Hsinchu, Taiwan.
Wang
Fu-Der
FD
Yen
Yung-Feng
YF
Lin
Mei-Lin
ML
Liu
Cheng-Yi
CY
D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D002438:Cefoperazone / Q000494:pharmacology*; D004359:Drug Therapy, Combination; D004791:Enzyme Inhibitors / Q000494:pharmacology; D006090:Gram-Negative Bacteria / Q000145:classification / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D010397:Penicillanic Acid / Q000031:analogs & derivatives / Q000494:pharmacology; D010878:Piperacillin / Q000494:pharmacology*; D013407:Sulbactam / Q000494:pharmacology; D000078142:Tazobactam; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams / Q000494:pharmacology*
D000900:Anti-Bacterial Agents; D004791:Enzyme Inhibitors; D065093:beta-Lactamase Inhibitors; D047090:beta-Lactams; D002438:Cefoperazone; D010397:Penicillanic Acid; D013407:Sulbactam; D000078142:Tazobactam; D010878:Piperacillin